Results 171 to 180 of about 8,113 (209)
Some of the next articles are maybe not open access.
American Journal of Cardiovascular Drugs, 2002
Bosentan is a nonpeptide, specific, competitive, dual antagonist at both endothelin receptor subtypes (ET(A) and ET(B)). Orally administered bosentan effectively prevents endothelin 1-induced vasoconstriction in pulmonary vessels in patients with pulmonary arterial hypertension.
Caroline M. Perry, Amitabh Prakash
openaire +5 more sources
Bosentan is a nonpeptide, specific, competitive, dual antagonist at both endothelin receptor subtypes (ET(A) and ET(B)). Orally administered bosentan effectively prevents endothelin 1-induced vasoconstriction in pulmonary vessels in patients with pulmonary arterial hypertension.
Caroline M. Perry, Amitabh Prakash
openaire +5 more sources
Expert Opinion on Pharmacotherapy, 2010
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +5 more sources
Pulmonary arterial hypertension (PAH) is a morbid condition with high mortality if left untreated. Bosentan is an effective treatment option for group 1 pulmonary arterial hypertension. Bosentan improves exercise tolerance and functional class and delays the time to clinical worsening in these patients.
Michael A, Mathier, David, Ishizawar
openaire +5 more sources
Expert Review of Cardiovascular Therapy, 2004
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +2 more sources
Bosentan (Tracleer, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period.
Kelly, Chin, Richard, Channick
openaire +2 more sources
Expert Opinion on Investigational Drugs, 1998
This article describes the pharmacological properties and the overall preclinical and clinical profiling of bosentan (Ro 47-0203), a non-peptide endothelin receptor antagonist with oral activity. Bosentan is a combined and competitive antagonist of both ETA and ETB receptors that is selective for the endothelin system.
Sylvie I. Ertel +3 more
openaire +3 more sources
This article describes the pharmacological properties and the overall preclinical and clinical profiling of bosentan (Ro 47-0203), a non-peptide endothelin receptor antagonist with oral activity. Bosentan is a combined and competitive antagonist of both ETA and ETB receptors that is selective for the endothelin system.
Sylvie I. Ertel +3 more
openaire +3 more sources
Bosentan and Warfarin Interaction
Annals of Pharmacotherapy, 2003OBJECTIVE: To report a case of decreased international normalized ratio (INR) in a patient receiving warfarin and bosentan. CASE SUMMARY: A 35-year-old African American woman with a history of primary pulmonary hypertension managed with warfarin, diltiazem, and hydrochlorothiazide was initiated on bosentan therapy. The patient's INR had been stable and
Lisa M. Murphey, Elizabeth H Hood
openaire +2 more sources
Delayed hypersensitivity to bosentan
Allergy, 2009This is the first case of a cell-mediated hypersensitivity to bosentan diagnosed on the basis of positive responses to the lymphocyte transformation test and a challenge. However, the latter provoked a severe reaction (DRESS)
A. Romano +5 more
openaire +3 more sources
Desmethyl bosentan displays a similar in vitro interaction profile as bosentan
Pulmonary Pharmacology & Therapeutics, 2015The endothelin-1 receptor antagonists bosentan and ambrisentan used for the treatment of pulmonary arterial hypertension remarkably differ in their potential to act as perpetrators in pharmacokinetic drug-drug interactions. So far, it is not clear whether the metabolites of bosentan and ambrisentan contribute to the extent of drug interactions.
Johanna Weiss +3 more
openaire +3 more sources